Walleye Capital’s Xeris Biopharma Holdings XERS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-611,296
Closed -$4.84M – 6250
2026
Q2
$4.84M Buy
+611,296
New +$3.9M 0.02% 847
2025
Q4
– Sell
-623,962
Closed -$5.08M – 5212
2025
Q3
$5.08M Buy
623,962
+380,687
+156% +$2.53M 0.02% 917
2025
Q2
$1.14M Sell
243,275
-448,444
-65% -$2.05M ﹤0.01% 1948
2025
Q1
$3.8M Buy
+691,719
New +$2.79M 0.02% 964
2024
Q4
– Sell
-1,121,738
Closed -$3.2M – 5652
2024
Q3
$3.2M Buy
+1,121,738
New +$2.88M 0.01% 1531
2024
Q1
– Sell
-35,927
Closed -$84.4K – 5960
2023
Q4
$84.4K Sell
35,927
-88,763
-71% -$164K ﹤0.01% 4117
2023
Q3
$232K Buy
+124,690
New +$286K ﹤0.01% 3437
2020
Q2
– Sell
-113,269
Closed -$221K – 1014
2020
Q1
$221K Buy
+113,269
New +$487K 0.05% 420

Other funds holding XERS

Walleye Capital's XERS Position: Q3 2026 in Review

Walleye Capital sold out of Xeris Biopharma Holdings (XERS) in Q3 2026, closing a stake of 611,296 shares — an estimated $4.84M sold.

Walleye Capital first reported a position in XERS in Q1 2020 and held it in 8 quarters. The position peaked at $5.08M in Q3 2025. 249 funds tracked by Wall St. Rank hold XERS as of Q3 2026.

  • Walleye Capital reported no remaining Xeris Biopharma Holdings position as of Q3 2026 after selling out during the quarter.
  • Walleye Capital sold 611,296 Xeris Biopharma Holdings shares in Q3 2026, an estimated $4.84M.
  • Walleye Capital first reported a position in Xeris Biopharma Holdings in Q1 2020 and held it in 8 quarters.
  • Walleye Capital's Xeris Biopharma Holdings position peaked at $5.08M in Q3 2025.
  • 249 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q3 2026.

Based on Walleye Capital's 13F filing for Q3 2026, filed 13 Nov 2026.